Intellia Therapeutics Stock Target Price and Analyst Consensus
| NTLA Stock | USD 9.58 0.44 4.81% |
The prevalent analyst and expert consensus on Intellia Therapeutics is Strong Buy with 17 strong buy estimates. The prevailing projected target price is 57.76 with 28 professional opinions. Intellia Therapeutics buy-or-sell recommendation and consensus module provides average expert sentiment on the projected Intellia Therapeutics target price to derive its highest and lowest estimates based on target price volatility of 4.8435.
Lowest Forecast 52.56 | Highest Forecast 64.12 | Target Price 57.76 |
Intellia |
It's important to approach Intellia Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Intellia Therapeutics Target Price Consensus
Intellia target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Intellia Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 28 | Strong Buy |
Most Intellia analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Intellia stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Intellia Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationIntellia Therapeutics Target Price Projection
Intellia Therapeutics' current and average target prices are 9.58 and 57.76, respectively. The current price of Intellia Therapeutics is the price at which Intellia Therapeutics is currently trading. On the other hand, Intellia Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Intellia Therapeutics Market Quote on 18th of March 2025
Target Price
Analyst Consensus On Intellia Therapeutics Target Price
Intellia Therapeutics Analyst Ratings
Intellia Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Intellia Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Intellia Therapeutics' financials, market performance, and future outlook by experienced professionals. Intellia Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Intellia Therapeutics price targets
Intellia Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Intellia Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Intellia Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Intellia Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Intellia Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Intellia Therapeutics is a key component of Intellia Therapeutics valuation and have some predictive power on the future returns of a Intellia Therapeutics.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Warren Buffett Holdings Invested few shares | |
 | ESG Investing Invested few shares | |
 | Hedge Favorites Invested few shares | |
 | Cash Cows Invested few shares | |
 | Business Services Invested few shares | |
 | Driverless Cars Invested over 60 shares | |
 | Macroaxis Picks Invested few shares | |
 | SRI Sustainable Growth Invested over 40 shares | |
 | Apparel Invested over 40 shares | |
 | Casinos Sold over 90 shares | |
 | Macroaxis Index Sold over 90 shares | |
 | Basic Utilities Invested over 90 shares | |
Check out Macroaxis Advice on Intellia Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Please note, the presentation of Intellia Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Intellia Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Intellia Therapeutics' management manipulating its earnings.